A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01638000

Acronym

BEYOND

Enrollment

1887

Registered

2012-07-11

Start date

2012-06-12

Completion date

2013-04-24

Last updated

2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder Diseases, Urinary Bladder, Overactive, Urologic Diseases

Keywords

Vesitrim, Frequency, Urgency, Urgency incontinence, Urinary incontinence, Overactive Bladder (OAB), Micturition, Mirabegron, YM178, Vesicare, Solifenacin

Brief summary

The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.

Interventions

DRUGMirabegron

oral tablet

DRUGSolifenacin succinate

oral tablet

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subject is willing and able to complete the micturition diary and questionnaires correctly * Subject has symptoms of OAB (urinary frequency and urgency with or without urgency incontinence) for at least 3 months * Subject is currently or has previously received at least one antimuscarinic agent intended to treat their OAB. The last antimuscarinic must have been taken for at least 4 weeks and taken within 6 months prior to the Screening Visit

Exclusion criteria

* Female subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential is sexually active and not practicing a highly reliable method of birth control * Subject has neurogenic bladder * Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator (for female subjects confirmed by a cough provocation test) * Subject has an indwelling catheter or practices intermittent self-catheterization * Subject has diabetic neuropathy * Subject has evidence of a symptomatic urinary tract infection, chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy or previous or current malignant disease of the pelvic organs * Subject has uncontrolled narrow angle glaucoma, urinary or gastric retention, severe ulcerative colitis, toxic megacolon, myasthenia gravis or any other medical condition which makes the use of anticholinergics contraindicated * The subject is currently receiving or has a history of treatment with intravesical botulinum toxin (cosmetic use is acceptable) or resiniferatoxin within 9 months prior to screening * Subject receives non-drug treatment including electro-stimulation therapy (with the exception of a bladder training program or pelvic floor exercises which started more than 30 days prior to screening) * Subject has moderate to severe hepatic impairment * Subject has severe renal impairment or end stage renal disease * Subject has severe uncontrolled hypertension * Subject has a clinically significant abnormal electrocardiogram (ECG) or has a known history of QT prolongation or currently taking medication known to prolong the QT interval * Subject has a known or suspected hypersensitivity to solifenacin, mirabegron or any of the inactive ingredients * Subject has a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening * Subject has been treated with an experimental device within 30 days or received an experimental agent within the longer of 30 days or five half-lives * Subject is using prohibited medications which cannot be stopped safely at the Screening Visit. Subject is excluded if using restricted medications not meeting protocol-specified criteria * Subject's last antimuscarinic treatment was solifenacin

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours	Baseline and final visit (up to Week 12)	A micturition is any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Secondary

Measure	Time frame	Description
Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Baseline and Week 4, Week 8, Week 12	—
Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4, Week 8, Week 12	An incontinence episode is any involuntary leakage of urine. The total number of incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.
Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Baseline and Week 4, Week 8, Week 12	An incontinence episode is any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4, Week 8, Week 12	An urgency incontinence episode is any involuntary leakage of urine accompanied by or immediately proceeded by urgency. The total number of urgency incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.
Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Baseline and Week 4, Week 8, Week 12	An urgency incontinence episode is any involuntary leakage of urine accompanied by or immediately proceeded by urgency. The mean number of urgency incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Baseline and Week 4, Week 8, Week 12	An urgency episode is a sudden compelling desire to pass urine immediately followed by an incontinent event or the patient having to rush to the toilet and make it in time; severity recorded as 3 (severe urgency) or 4 (urgency incontinence) on the Patient Perception of the Intensity of Urgency Scale (PPIUS) validated scale. The mean number of urgency episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Baseline and Week 4, Week 8, Week 12	Urgency level was rated by the participant during the 3-day micturition diary period using the PPIUS 5-point categorical scale: 0. No urgency; 1. Mild urgency; 2. Moderate urgency; 3. Severe urgency; 4. Urgency incontinence.
Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4, Week 8, Week 12	The total number of pads per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.
Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Baseline and Week 4, Week 8 , Week 12	The mean number of pads per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4, Week 8, Week 12	A nocturia episode is defined as waking at night ≥1 times to void (i.e., any voiding associated with sleep disturbance between the time the patient goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The total number of nocturia episodes were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.
Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Baseline and Week 4, Week 8, Week 12	A nocturia episode is defined as waking at night ≥1 times to void (i.e., any voiding associated with sleep disturbance between the time the patient goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.
Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 4, Week 8, Week 12	A responder is defined as a participant who has ≥8 micturitions at baseline and has \<8 micturitions per 24 hours during the treatment period at each specified visit, where change from baseline is \<0.
Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4, Week 8, Week 12	A responder is defined as a participant with at least 50% decrease from baseline in mean number of incontinence episodes per 24 hours during the treatment period at specified visit.
Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4, Week 8, Week 12	A responder is defined as a participant who reported incontinence episodes at baseline and reported no incontinence episodes during the treatment period at specified visit.
Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Baseline and Week 4	The European Quality of Life 5-Dimensions Questionnaire (EQ-5D-5L) is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 4	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 4	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 4	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 4	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 8	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 8	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 8	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 8	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 8	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 12	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 12	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 12	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 12	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and Week 12	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and final visit (up to Week 12)	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and final visit (up to Week 12)	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and final visit (up to Week 12)	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and final visit (up to Week 12)	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Baseline and final visit (up to Week 12)	The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).
Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Baseline and Week 4, Week 8, Week 12	The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, scored from 1 to 6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.
Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Baseline and Week 4, Week 8, Week 12	The OAB-q is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping, concern, sleep, social interaction). The total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.
Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Baseline and Week 4, Week 8, Week 12	The Patient Perception of Bladder Condition (PPBC) questionnaire is a single-item questionnare used to assess participants' perceptions and impressions of their bladder condition. Participants assessed their bladder condition using a 6-point categorical scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.
Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)	Baseline and Week 12	The Treatment Satisfaction (TS)-Visual Analogue Scale (VAS) was a self-rated scale with the participant answering the question Are you satisfied with your treatment? and placing a vertical mark on a line from 0 (No, not at all) to 10 (Yes, completely).
Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale	Baseline and Week 12	The Treatment Satisfaction (TS)-Likert Scale was a self-rated scale with the participant answering the question How satisfied were you with your treatment? with on a scale from 1 (extremely dissatisfied) to 7 (extremely satisfied).
Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit	Baseline to Week 12	A responder is defined as a participant with ≥10 points improvement in symptom bother from baseline.
Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	From first dose of study drug up to 30 days after last dose of study drug (up to 16 weeks)	A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE; defined as any untoward medical occurrence in a patient administered a study drug) that started or worsened in the period from the first double-blind medication intake until 30 days after the last double-blind medication intake. The following TEAEs were selected for inclusion in the analysis: Dry mouth (aptyalism, dry mouth, dry throat), constipation (constipation), blurred vision (vision blurred, myopia, refraction disorder, accommodation disorder).
Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	Baseline to Week 12	A responder is defined as a participant with ≥1, ≥2, ≥3, ≥4, ≥5 or 6-point improvement from baseline in TS-Likert scale.
Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	Baseline to final visit (up to Week 12)	A responder is defined as a participant with \>=1 or \>=2 or \>=3 or \>=4 or \>=5 or 6-point improvement from baseline in TS-Likert scale.
Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit	Baseline to Week 12	A responder is defined as a participant with ≥1 point improvement in PPBC from baseline.
Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit	Baseline to Week 12	A responder is defined as a participant with ≥2 point improvement in PPBC from baseline.
Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit	Baseline to Week 12	A responder is defined as a participant with \>=10 points improvement in the total HRQL score from baseline.

Countries

Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey (Türkiye), Ukraine, United Kingdom

Participant flow

Recruitment details

Participants recruited for this study were men and women with overactive bladder (OAB) who had received 1 or more antimuscarinics in the past and who were dissatisfied with their last antimuscarinic treatment due to lack of efficacy (provided that their previous antimuscarinic was not solifenacin).

Pre-assignment details

Participants entered a 2-week, single-blind, placebo run-in period and completed a daily diary (including 3 consecutive days prior to the randomization visit for micturition and incontinence). After this, participants' eligibility criteria were re-confirmed and they were then randomized into the double-blind treatment period of the study.

Participants by arm

Arm	Count
Mirabegron 50 mg Participants who received mirabegron 50 mg once daily for 12 weeks.	936
Solifenacin 5 mg Participants who received solifenacin 5 mg once daily for 12 weeks.	934
Total	1,870

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Adverse Event	14	16
Overall Study	Lack of Efficacy	5	6
Overall Study	Miscellaneous	2	2
Overall Study	Protocol Violation	11	13
Overall Study	Randomized but Never Received Drug	7	10
Overall Study	Withdrawal by Subject	21	24

Baseline characteristics

Characteristic	Solifenacin 5 mg	Total	Mirabegron 50 mg
Age, Continuous	57.4 years STANDARD_DEVIATION 13.6	57.0 years STANDARD_DEVIATION 13.93	56.7 years STANDARD_DEVIATION 14.25
Mean Incontinence Episodes / 24 hours	2.1 incontinence episodes STANDARD_DEVIATION 2.05	2.1 incontinence episodes STANDARD_DEVIATION 2.17	2.1 incontinence episodes STANDARD_DEVIATION 2.3
Mean Level of Urgency	2.6 units on a scale STANDARD_DEVIATION 0.49	2.6 units on a scale STANDARD_DEVIATION 0.49	2.6 units on a scale STANDARD_DEVIATION 0.49
Mean Micturitions / 24 hours	11.4 micturitions STANDARD_DEVIATION 2.89	11.5 micturitions STANDARD_DEVIATION 3.08	11.6 micturitions STANDARD_DEVIATION 3.25
Mean Nocturia Episodes / 24 hours	2.3 nocturia episodes STANDARD_DEVIATION 1.42	2.3 nocturia episodes STANDARD_DEVIATION 1.41	2.3 nocturia episodes STANDARD_DEVIATION 1.41
Mean Number of Pads Used / 24 hours	3.3 pads STANDARD_DEVIATION 3.7	3.2 pads STANDARD_DEVIATION 3.57	3.1 pads STANDARD_DEVIATION 3.43
Mean Urgency Episodes (grade 3 or 4) / 24 hours	7.8 urgency episodes STANDARD_DEVIATION 4.46	7.8 urgency episodes STANDARD_DEVIATION 4.61	7.7 urgency episodes STANDARD_DEVIATION 4.75
Mean Urgency Incontinence Episodes / 24 hours	2.0 urgency incontinence episodes STANDARD_DEVIATION 1.94	2.0 urgency incontinence episodes STANDARD_DEVIATION 1.96	1.9 urgency incontinence episodes STANDARD_DEVIATION 1.99
Sex: Female, Male Female	709 Participants	1421 Participants	712 Participants
Sex: Female, Male Male	225 Participants	449 Participants	224 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	29 / 936	54 / 934
serious Total, serious adverse events	14 / 936	13 / 934

Outcome results

Primary

Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours

A micturition is any voluntary urination (excluding incontinence only episodes). The mean number of micturitions per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and final visit (up to Week 12)

Population: Per Protocol Set (PPS) - all randomized participants who took ≥1 dose of double-blind study drug and who recorded ≥1 micturition in the baseline diary and ≥1 micturition in a post-baseline diary who had completed the study with no major protocol violations which could impact the primary endpoint. Last observation carried forward (LOCF) was used.

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours	-2.95 micturitions	Standard Error 0.087
Solifenacin 5 mg	Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours	-3.13 micturitions	Standard Error 0.088

Comparison: The non-inferiority of mirabegron vs. solifencacin on the change from baseline to final visit in the mean number of micturitions per 24 hours.p-value: 0.1595% CI: [-0.42, 0.06]ANCOVA

Secondary

Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment

A nocturia episode is defined as waking at night ≥1 times to void (i.e., any voiding associated with sleep disturbance between the time the patient goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The mean number of nocturia episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. Only participants with at least one nocturia episode at baseline were included in the analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 4 [N=877,871]	-0.72 nocturia episodes	Standard Error 0.033
Mirabegron 50 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 8 [N=850,844]	-0.90 nocturia episodes	Standard Error 0.031
Mirabegron 50 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 12 [N=831,828]	-0.98 nocturia episodes	Standard Error 0.032
Solifenacin 5 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 4 [N=877,871]	-0.63 nocturia episodes	Standard Error 0.034
Solifenacin 5 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 8 [N=850,844]	-0.87 nocturia episodes	Standard Error 0.031
Solifenacin 5 mg	Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 12 [N=831,828]	-0.97 nocturia episodes	Standard Error 0.033

Comparison: Week 4 Difference vs. Mirabegron. Differences of adjusted means were calculated by subtracting the adjusted mean of mirabegron 50 mg from the adjusted mean of solifenacin 5 mg.p-value: 0.05895% CI: [0, 0.18]ANCOVA

Comparison: Week 8 Difference vs. Mirabegron. Differences of adjusted means were calculated by subtracting the adjusted mean of mirabegron 50 mg from the adjusted mean of solifenacin 5 mg.p-value: 0.595% CI: [-0.06, 0.12]ANCOVA

Comparison: Week 12 Difference vs. Mirabegron. Differences of adjusted means were calculated by subtracting the adjusted mean of mirabegron 50 mg from the adjusted mean of solifenacin 5 mg.p-value: 0.8195% CI: [-0.08, 0.1]ANCOVA

Secondary

Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment

The mean number of pads per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and Week 4, Week 8 , Week 12

Population: FAS population. Only participants with at least one pad used at baseline were included in this analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 4 [M=574,563]	-1.80 pads	Standard Error 0.081
Mirabegron 50 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 8 [N=551,543]	-2.10 pads	Standard Error 0.07
Mirabegron 50 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 12 [N=543,532]	-2.14 pads	Standard Error 0.078
Solifenacin 5 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 12 [N=543,532]	-2.20 pads	Standard Error 0.079
Solifenacin 5 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 4 [M=574,563]	-1.82 pads	Standard Error 0.081
Solifenacin 5 mg	Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment	Week 8 [N=551,543]	-2.14 pads	Standard Error 0.07

Secondary

Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency

Urgency level was rated by the participant during the 3-day micturition diary period using the PPIUS 5-point categorical scale: 0. No urgency; 1. Mild urgency; 2. Moderate urgency; 3. Severe urgency; 4. Urgency incontinence.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. LOCF was used in final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 4 [N=916,906]	-0.36 units on a scale	Standard Error 0.016
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 12 [N=870,856]	-0.60 units on a scale	Standard Error 0.023
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 8 [N=888,876]	-0.50 units on a scale	Standard Error 0.019
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Final visit [N=920,910]	-0.58 units on a scale	Standard Error 0.022
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Final visit [N=920,910]	-0.57 units on a scale	Standard Error 0.022
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 4 [N=916,906]	-0.36 units on a scale	Standard Error 0.017
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 8 [N=888,876]	-0.52 units on a scale	Standard Error 0.019
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency	Week 12 [N=870,856]	-0.60 units on a scale	Standard Error 0.023

Comparison: Final visit Difference vs. Mirabegron. Differences of adjusted means were calculated by subtracting the adjusted mean of mirabegron 50 mg from the adjusted mean of solifenacin 5 mg.p-value: 0.7495% CI: [-0.05, 0.07]ANCOVA

Secondary

Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours

An urgency episode is a sudden compelling desire to pass urine immediately followed by an incontinent event or the patient having to rush to the toilet and make it in time; severity recorded as 3 (severe urgency) or 4 (urgency incontinence) on the Patient Perception of the Intensity of Urgency Scale (PPIUS) validated scale. The mean number of urgency episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. Only participants with at least one urgency episode (grade 3 or 4) at baseline were included in this analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 4 [N=915,905]	-3.75 urgency episodes	Standard Error 0.113
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 8 [N=887,875]	-4.44 urgency episodes	Standard Error 0.111
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 12 [N=869,855]	-4.67 urgency episodes	Standard Error 0.116
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Final Visit [N=919,909]	-4.61 urgency episodes	Standard Error 0.115
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Final Visit [N=919,909]	-4.84 urgency episodes	Standard Error 0.115
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 12 [N=869,855]	-4.99 urgency episodes	Standard Error 0.117
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 4 [N=915,905]	-3.88 urgency episodes	Standard Error 0.114
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours	Week 8 [N=887,875]	-4.79 urgency episodes	Standard Error 0.112

Comparison: Final Visit Difference vs. Mirabegron. Differences of adjusted means were calculated by subtracting the adjusted mean of mirabegron 50 mg from the adjusted mean of solifenacin 5 mg.p-value: 0.1695% CI: [-0.55, 0.09]ANCOVA

Secondary

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours

An incontinence episode is any involuntary leakage of urine. The mean number of incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS-I population. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 4 [N=404,410]	-1.22 incontinence episodes	Standard Error 0.063
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 8 [N=387,397]	-1.37 incontinence episodes	Standard Error 0.093
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 12 [N=381,387]	-1.41 incontinence episodes	Standard Error 0.115
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 4 [N=404,410]	-1.30 incontinence episodes	Standard Error 0.063
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 8 [N=387,397]	-1.59 incontinence episodes	Standard Error 0.092
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours	Week 12 [N=381,387]	-1.66 incontinence episodes	Standard Error 0.114

Comparison: Week 12 Difference vs. Mirabegron. Difference of the adjusted mean is calculated by subtracting the adjusted mean of mirabegron from the adjusted mean of solifenacin.p-value: 0.4795% CI: [-0.57, 0.07]ANCOVA

Secondary

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours

Time frame: Baseline and Week 4, Week 8, Week 12

Population: Full Analysis Set (FAS) - consisted of all randomized participants who took ≥ 1 dose of double-blind study drug and who recorded ≥1 micturition measurement in the baseline diary and ≥1 micturition measurement in a post-baseline diary. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 4 [N=916,906]	-2.37 micturitions	Standard Error 0.083
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 8 [N=888,876]	-2.77 micturitions	Standard Error 0.084
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 12 [N=870,856]	-3.02 micturitions	Standard Error 0.088
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 4 [N=916,906]	-2.33 micturitions	Standard Error 0.083
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 8 [N=888,876]	-3.00 micturitions	Standard Error 0.085
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours	Week 12 [N=870,856]	-3.21 micturitions	Standard Error 0.089

Secondary

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours

An urgency incontinence episode is any involuntary leakage of urine accompanied by or immediately proceeded by urgency. The mean number of urgency incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS-I population. Only participants with at least one urgency incontinence episode at baseline were included in the analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 4 [N=395,399]	-1.22 urgency incontinence episodes	Standard Error 0.057
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 8 [N=379,386]	-1.39 urgency incontinence episodes	Standard Error 0.05
Mirabegron 50 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 12 [N=373,377]	-1.49 urgency incontinence episodes	Standard Error 0.047
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 4 [N=395,399]	-1.24 urgency incontinence episodes	Standard Error 0.057
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 8 [N=379,386]	-1.56 urgency incontinence episodes	Standard Error 0.05
Solifenacin 5 mg	Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours	Week 12 [N=373,377]	-1.59 urgency incontinence episodes	Standard Error 0.047

Secondary

Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

The EQ-5D-5L is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).

Time frame: Baseline and final visit (up to Week 12)

Population: FAS population who has non-missing values at both Baseline and specified visit. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	38 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	25 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	8 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	12 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	133 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	55 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	10 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	6 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	52 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	92 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	22 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	26 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	55 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	332 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	356 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	52 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	121 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	83 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	17 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	68 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	45 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	29 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	35 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	18 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	15 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	7 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and final visit (up to Week 12)

Population: FAS population who has non-missing values at both Baseline and specified visit. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	53 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	17 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	6 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	20 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	80 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	60 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	14 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	33 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	45 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	36 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	16 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	5 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	37 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	460 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	471 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	25 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	12 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	88 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	34 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	18 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	67 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	46 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	31 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	52 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	17 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	11 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	11 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and final visit (up to Week 12)

Population: FAS population who has non-missing values at both Baseline and specified visit. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	39 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	16 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	16 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	116 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	80 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	51 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	103 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	48 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	30 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	55 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	297 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	306 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	52 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	13 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	118 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	93 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	20 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	83 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	72 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	44 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	7 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	34 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	14 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	5 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	5 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and final visit (up to Week 12)

Population: FAS population who has non-missing values at both Baseline and specified visit. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	27 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	5 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	43 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	45 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	8 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	6 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	25 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	5 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	8 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	697 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	25 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	26 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	7 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	43 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	14 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	46 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	8 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	699 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants

Secondary

Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and final visit (up to Week 12)

Population: FAS population who has non-missing values at both Baseline and specified visit. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	31 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	9 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	6 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	106 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	83 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problem	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	42 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problem	2 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	45 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problem	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	29 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problem	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	46 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	444 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	440 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	49 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	8 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	113 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	54 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	9 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	79 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	34 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	20 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	41 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	14 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	8 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	7 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problem	2 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problem	3 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problem	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problem	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	8 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale

The Treatment Satisfaction (TS)-Likert Scale was a self-rated scale with the participant answering the question How satisfied were you with your treatment? with on a scale from 1 (extremely dissatisfied) to 7 (extremely satisfied).

Time frame: Baseline and Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale	Week 12 [N=876,871]	2.92 units on a scale	Standard Error 0.05
Mirabegron 50 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale	Final visit [N=897,889]	2.88 units on a scale	Standard Error 0.05
Solifenacin 5 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale	Week 12 [N=876,871]	3.07 units on a scale	Standard Error 0.05
Solifenacin 5 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale	Final visit [N=897,889]	3.03 units on a scale	Standard Error 0.05

Comparison: Final Visit Difference vs. Mirabegron. Difference of the adjusted mean is calculated by subtracting the adjusted mean of mirabegron from the adjusted mean of solifenacin.p-value: 0.03495% CI: [0.01, 0.29]ANCOVA

Secondary

Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)

The Treatment Satisfaction (TS)-Visual Analogue Scale (VAS) was a self-rated scale with the participant answering the question Are you satisfied with your treatment? and placing a vertical mark on a line from 0 (No, not at all) to 10 (Yes, completely).

Time frame: Baseline and Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)	Week 12 [N=865,857]	3.51 units on a scale	Standard Error 0.099
Mirabegron 50 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)	Final visit [N=891,876]	3.44 units on a scale	Standard Error 0.099
Solifenacin 5 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)	Week 12 [N=865,857]	3.93 units on a scale	Standard Error 0.1
Solifenacin 5 mg	Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)	Final visit [N=891,876]	3.86 units on a scale	Standard Error 0.1

Secondary

Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 12

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	38 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	16 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	25 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	132 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	52 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	51 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	84 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	18 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	53 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	323 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	341 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	48 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	20 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	118 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	80 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	67 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	44 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	28 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	35 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	14 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 12

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	43 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	35 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	18 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	26 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	6 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	77 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	6 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	57 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	442 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	36 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	31 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	53 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	16 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	82 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	32 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	51 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	8 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	10 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	11 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	63 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	43 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	30 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	459 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	25 participants

Secondary

Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 12

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	39 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	17 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	14 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	16 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	12 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	112 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	79 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	49 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	97 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	42 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	29 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	50 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	10 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	287 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	299 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	49 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	15 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	116 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	87 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	18 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	10 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	80 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	71 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	38 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	13 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	34 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	13 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 12

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	25 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	36 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	667 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	44 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	43 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	13 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	14 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	23 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	36 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	42 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	46 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	25 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	670 participants

Secondary

Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 12

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	31 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	27 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	6 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	6 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	103 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	81 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	14 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	41 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	45 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	25 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	43 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	425 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	426 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	45 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	22 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	107 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	53 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	79 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	31 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	9 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	40 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	13 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	8 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 4

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	32 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	98 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	25 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	64 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	122 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	37 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	29 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	59 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	328 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	339 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	65 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	102 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	94 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	25 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	33 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	65 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	40 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	29 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	19 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	9 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire

The European Quality of Life 5-Dimensions Questionnaire (EQ-5D-5L) is a standardized nondisease specific (i.e., generic) instrument for use as a measure of health outcome. It has 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. Each dimension has 5 response levels (e.g., no problems with performing activity, slight problems, moderate problems, severe problems, unable to perform \[extreme problems\]).

Time frame: Baseline and Week 4

Population: FAS population who have non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> moderate problems	45 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> slight problems	47 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> severe problems	16 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> no problems	39 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> slight problems	39 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> no problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> moderate problems	24 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> moderate problems	50 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> severe problems	6 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> no problems	66 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> no problems	20 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> slight problems	24 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> No problems	447 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Slight problems	45 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Moderate problems	23 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Slight problems	43 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Moderate problems	19 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> Extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> no problems	80 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> slight problems	47 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> moderate problems	11 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Slight problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> no problems	51 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> slight problems	45 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> moderate problems	46 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Moderate problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> no problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> slight problems	34 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> moderate problems	29 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> severe problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Severe problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No data -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire	No problems -> No problems	443 participants

Secondary

Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 4

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	60 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	299 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	57 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	101 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	116 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	32 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	51 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	66 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extrme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	21 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	22 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	19 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	20 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	65 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	97 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	19 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	109 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	25 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extrme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	25 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	285 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	67 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	44 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	86 participants

Secondary

Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 4

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	5 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	13 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> No problems	37 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	24 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	18 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	28 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	17 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> No problems	693 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> No problems	703 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	23 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> No problems	41 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	17 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	28 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 4

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	17 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	21 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	11 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	102 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	47 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	20 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	59 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	49 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	45 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	14 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	61 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	421 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	422 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	63 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	10 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	101 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	58 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	34 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	59 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	39 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	28 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	19 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	13 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 8

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	11 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	11 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	50 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	325 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	52 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	42 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	10 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	122 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	94 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	31 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	23 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	6 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	39 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	49 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	59 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	34 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	5 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	13 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	37 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	11 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	10 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	20 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	334 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	65 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	8 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	13 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	116 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	79 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	2 participants

Secondary

Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 8

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	30 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	14 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	30 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	21 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	20 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	6 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	70 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	51 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	20 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	41 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	46 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> modrate problems	31 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	8 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	19 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	38 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	445 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	446 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	31 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	23 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	11 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	78 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	44 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	47 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	52 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> modrate problems	40 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	22 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	41 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	8 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	7 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants

Secondary

Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 8

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	17 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	13 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	10 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	103 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	111 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	25 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	6 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	59 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	66 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	46 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	37 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	18 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	8 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	291 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	52 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	66 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	57 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	286 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	10 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	96 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	103 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	30 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	5 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	61 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	78 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	8 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	25 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	7 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	1 participants

Secondary

Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 8

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	672 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	35 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	20 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	42 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	19 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> exteme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	34 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	17 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	17 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	9 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	4 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	34 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	8 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	13 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	21 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	673 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	38 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	33 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	20 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	9 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> exteme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	0 participants

Secondary

Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Time frame: Baseline and Week 8

Population: FAS population who has non-missing values at both Baseline and specified visit.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	16 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	430 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	48 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	15 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	16 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	6 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	45 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	101 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	61 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	57 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	26 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	10 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	13 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	23 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	12 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	7 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	2 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	1 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	3 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	5 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Mirabegron 50 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no data	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> moderate problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no problems	426 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no problems	16 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> slight problems	49 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> moderate problems	11 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> slight problems	32 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> severe problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> moderate problems	15 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No problems -> no data	13 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> extreme problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no problems	109 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> severe problems	3 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> slight problems	50 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> extreme problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> moderate problems	12 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> severe problems	2 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> slight problems	1 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Severe problems -> no data	5 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Slight problems -> no data	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> moderate problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> no problems	53 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no problems	4 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> slight problems	53 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> no data	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> extreme problems	0 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> moderate problems	20 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Extreme problems -> slight problems	5 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	Moderate problems -> severe problems	6 participants
Solifenacin 5 mg	Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire	No data -> severe problems	0 participants

Secondary

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)

The Patient Perception of Bladder Condition (PPBC) questionnaire is a single-item questionnare used to assess participants' perceptions and impressions of their bladder condition. Participants assessed their bladder condition using a 6-point categorical scale: 1. Does not cause me any problems at all; 2. Causes me some very minor problems; 3. Causes me some minor problems; 4. Causes me (some) moderate problems; 5. Causes me severe problems; 6. Causes me many severe problems.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 4 [N=905,896]	-0.91 units on a scale	Standard Error 0.035
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 8 [N=882,875]	-1.30 units on a scale	Standard Error 0.038
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 12 [N=865,858]	-1.58 units on a scale	Standard Error 0.042
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Final visit [N=906,897]	-1.53 units on a scale	Standard Error 0.042
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Final visit [N=906,897]	-1.67 units on a scale	Standard Error 0.042
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 4 [N=905,896]	-1.00 units on a scale	Standard Error 0.035
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 12 [N=865,858]	-1.73 units on a scale	Standard Error 0.042
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)	Week 8 [N=882,875]	-1.46 units on a scale	Standard Error 0.038

Comparison: Week 4 Difference vs. Mirabegron. Difference of the adjusted mean is calculated by subtracting the adjusted mean of mirabegron from the adjusted mean of solifenacin.p-value: 0.0795% CI: [-0.19, 0.01]ANCOVA

Comparison: Week 8 Difference vs. Mirabegron. Difference of the adjusted mean is calculated by subtracting the adjusted mean of mirabegron from the adjusted mean of solifenacin.p-value: 0.00395% CI: [-0.27, -0.06]ANCOVA

Comparison: Week 12 Difference vs. Mirabegron.Difference of the adjusted mean is calculated by subtracting the adjusted mean of mirabegron from the adjusted mean of solifenacin.p-value: 0.01595% CI: [-0.26, -0.03]ANCOVA

Secondary

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)

The Overactive Bladder Questionnaire (OAB-q) is a self-reported questionnaire with items relating to symptom bother and health-related quality of life (HRQoL). The symptom bother portion consists of 8 items, scored from 1 to 6. The total symptom bother score was calculated from the 8 answers and then transformed to range from 0 (least severity) to 100 (worst severity). A negative change from baseline indicates an improvement.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 4 [N=905,896]	-20.51 units on a scale	Standard Error 0.576
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 8 [N=882,875]	-25.96 units on a scale	Standard Error 0.599
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 12 [N=865,859]	-29.74 units on a scale	Standard Error 0.647
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Final visit [N=906,897]	-28.89 units on a scale	Standard Error 0.652
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 12 [N=865,859]	-31.84 units on a scale	Standard Error 0.649
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Final visit [N=906,897]	-30.76 units on a scale	Standard Error 0.655
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 8 [N=882,875]	-27.76 units on a scale	Standard Error 0.601
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)	Week 4 [N=905,896]	-22.20 units on a scale	Standard Error 0.579

Secondary

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q

The OAB-q is a self-reported questionnaire with items relating to Symptom Bother and health-related quality of life (HRQoL). The HRQoL portion consists of an 25-item HRQoL subscale containing the following domains scored from 1 to 6: coping, concern, sleep, social interaction). The total score is calculated by adding the 4 HRQoL subscale scores and transforming to a scale from 0 to 100, with higher scores indicating better quality of life. A positive change from baseline indicates an improvement.

Time frame: Baseline and Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (LEAST_SQUARES_MEAN)	Dispersion
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 4 [N=905,896]	17.09 units on a scale	Standard Error 0.543
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 8 [N=882,875]	21.66 units on a scale	Standard Error 0.568
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 12 [N=865,859]	25.31 units on a scale	Standard Error 0.611
Mirabegron 50 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Final visit [N=906,897]	24.53 units on a scale	Standard Error 0.616
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Final visit [N=906,897]	25.94 units on a scale	Standard Error 0.619
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 4 [N=905,896]	18.23 units on a scale	Standard Error 0.546
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 12 [N=865,859]	26.85 units on a scale	Standard Error 0.613
Solifenacin 5 mg	Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q	Week 8 [N=882,875]	23.20 units on a scale	Standard Error 0.57

Secondary

Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

An incontinence episode is any involuntary leakage of urine. The total number of incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS-Incontinence (FAS-I) - consisted of all FAS participants with ≥1 incontinence episode at baseline. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Mirabegron 50 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=404,410]	2.64 incontinence episodes	Standard Error 0.28
Mirabegron 50 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=387,397]	2.19 incontinence episodes	Standard Error 0.457
Mirabegron 50 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=381,387]	2.07 incontinence episodes	Standard Error 0.562
Mirabegron 50 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=404,413]	2.13 incontinence episodes	Standard Error 0.533
Solifenacin 5 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=404,413]	1.29 incontinence episodes	Standard Error 0.157
Solifenacin 5 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=404,410]	2.25 incontinence episodes	Standard Error 0.217
Solifenacin 5 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=381,387]	1.08 incontinence episodes	Standard Error 0.124
Solifenacin 5 mg	Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=387,397]	1.28 incontinence episodes	Standard Error 0.135

Comparison: Week 4 Rate Ratio vs. Mirabegron.p-value: 0.3395% CI: [0.73, 1.11]Poisson regression

Comparison: Week 8 Rate Ratio vs. Mirabegron.p-value: 0.2195% CI: [0.64, 1.1]Poisson regression

Comparison: Week 12 Rate Ratio vs. Mirabegron.p-value: 0.8395% CI: [0.71, 1.32]Poisson regression

Comparison: Final Visit Rate Ratio vs. Mirabegronp-value: 0.5795% CI: [0.68, 1.24]Poisson regression

Secondary

Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

A nocturia episode is defined as waking at night ≥1 times to void (i.e., any voiding associated with sleep disturbance between the time the patient goes to bed with the intention to sleep until the time the patient gets up in the morning with the intention to stay awake). The total number of nocturia episodes were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. Only participants with at least one nocturia episode at baseline were included in the analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Mirabegron 50 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=877,871]	4.78 nocturia episodes	Standard Error 0.12
Mirabegron 50 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=850, 844]	4.26 nocturia episodes	Standard Error 0.118
Mirabegron 50 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=831,828]	3.94 nocturia episodes	Standard Error 0.115
Mirabegron 50 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final Visit [N=879,875]	4.05 nocturia episodes	Standard Error 0.12
Solifenacin 5 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final Visit [N=879,875]	4.13 nocturia episodes	Standard Error 0.114
Solifenacin 5 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=877,871]	5.12 nocturia episodes	Standard Error 0.139
Solifenacin 5 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=831,828]	4.06 nocturia episodes	Standard Error 0.116
Solifenacin 5 mg	Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=850, 844]	4.41 nocturia episodes	Standard Error 0.117

Comparison: Week 4 Rate Ratio vs. Mirabegronp-value: 0.06895% CI: [1, 1.11]Poisson regression

Comparison: Week 8 Rate Ratio vs. Mirabegronp-value: 0.2195% CI: [0.98, 1.11]Poisson regression

Comparison: Week 12 Rate Ratio vs. Mirabegronp-value: 0.5295% CI: [0.95, 1.1]Poisson regression

Comparison: Final Visit Rate Ratio vs. Mirabegronp-value: 0.4495% CI: [0.96, 1.1]Poisson regression

Secondary

Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit

The total number of pads per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS population. LOCF was used in final visit only. Only participants with at least one pad used at baseline were included in this analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Mirabegron 50 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=574,563]	4.25 pads	Standard Error 0.324
Mirabegron 50 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=551,543]	3.33 pads	Standard Error 0.284
Mirabegron 50 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=543,532]	3.19 pads	Standard Error 0.304
Mirabegron 50 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=576,565]	3.32 pads	Standard Error 0.3
Solifenacin 5 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=576,565]	3.19 pads	Standard Error 0.248
Solifenacin 5 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=574,563]	4.26 pads	Standard Error 0.297
Solifenacin 5 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=543,532]	3.04 pads	Standard Error 0.244
Solifenacin 5 mg	Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=551,543]	3.27 pads	Standard Error 0.236

Comparison: Week 4 Rate Ratio vs. Mirabegronp-value: 0.6795% CI: [0.89, 1.2]Poisson regression

Comparison: Week 8 Rate Ratio vs. Mirabegronp-value: 0.07395% CI: [0.99, 1.39]Poisson regression

Comparison: Week 12 Rate Ratio vs. Mirabegronp-value: 0.2595% CI: [0.92, 1.37]Poisson regression

Comparison: Final Visit Rate Ratio vs. Mirabegronp-value: 0.495% CI: [0.9, 1.31]Poisson regression

Secondary

Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

An urgency incontinence episode is any involuntary leakage of urine accompanied by or immediately proceeded by urgency. The total number of urgency incontinence episodes per 24 hours were calculated from the data recorded by the participant during the 3-day micturition diary period prior to each visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS-I population. LOCF was used for final visit only. Only participants with at least one urgency incontinence episode at baseline were included in the analysis. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (MEAN)	Dispersion
Mirabegron 50 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=395,399]	2.27 urgency incontinence episodes	Standard Error 0.23
Mirabegron 50 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=379,386]	1.74 urgency incontinence episodes	Standard Error 0.227
Mirabegron 50 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=373,377]	1.44 urgency incontinence episodes	Standard Error 0.217
Mirabegron 50 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=395,402]	1.51 urgency incontinence episodes	Standard Error 0.211
Solifenacin 5 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Final visit [N=395,402]	1.23 urgency incontinence episodes	Standard Error 0.15
Solifenacin 5 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 4 [N=395,399]	2.16 urgency incontinence episodes	Standard Error 0.213
Solifenacin 5 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 12 [N=373,377]	1.03 urgency incontinence episodes	Standard Error 0.12
Solifenacin 5 mg	Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit	Week 8 [N=379,386]	1.13 urgency incontinence episodes	Standard Error 0.125

Comparison: Week 4 Rate Ratio vs. Mirabegronp-value: 0.4495% CI: [0.74, 1.14]Poisson regression

Comparison: Week 8 Rate Ratio vs. Mirabegronp-value: 0.1195% CI: [0.6, 1.06]Poisson regression

Comparison: Week 12 Rate Ratio vs. Mirabegronp-value: 0.7895% CI: [0.76, 1.45]Poisson regression

Comparison: Final Visit Rate Ratio vs. Mirabegronp-value: 0.8595% CI: [0.71, 1.33]Poisson regression

Secondary

Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period

A treatment-emergent adverse event (TEAE) was defined as an adverse event (AE; defined as any untoward medical occurrence in a patient administered a study drug) that started or worsened in the period from the first double-blind medication intake until 30 days after the last double-blind medication intake. The following TEAEs were selected for inclusion in the analysis: Dry mouth (aptyalism, dry mouth, dry throat), constipation (constipation), blurred vision (vision blurred, myopia, refraction disorder, accommodation disorder).

Time frame: From first dose of study drug up to 30 days after last dose of study drug (up to 16 weeks)

Population: SAF population

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Dry mouth	3.1 percentage of participants
Mirabegron 50 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Blurred vision	0.6 percentage of participants
Mirabegron 50 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Dry throat	0.1 percentage of participants
Mirabegron 50 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Constipation	2.2 percentage of participants
Mirabegron 50 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Overall	5 percentage of participants
Solifenacin 5 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Constipation	2.5 percentage of participants
Solifenacin 5 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Overall	7.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Dry mouth	5.8 percentage of participants
Solifenacin 5 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Dry throat	0.1 percentage of participants
Solifenacin 5 mg	Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period	Blurred vision	0.4 percentage of participants

Comparison: Difference vs Mirabegron. Differences of the percentages were calculated by subtracting the percentage of mirabegron 50 mg group from the percentage of solifenacin 5 mg group.p-value: 0.0395% CI: [1.04, 2.25]Regression, Logistic

Secondary

Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit

A responder is defined as a participant with at least 50% decrease from baseline in mean number of incontinence episodes per 24 hours during the treatment period at specified visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS-I population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4 [N=404,410]	75.5 percentage of participants
Mirabegron 50 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 8 [N=387,397]	85.5 percentage of participants
Mirabegron 50 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 12 [N=381,387]	86.1 percentage of participants
Mirabegron 50 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Final visit [N=404,413]	85.1 percentage of participants
Solifenacin 5 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Final visit [N=404,413]	88.1 percentage of participants
Solifenacin 5 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4 [N=404,410]	77.3 percentage of participants
Solifenacin 5 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 12 [N=381,387]	89.1 percentage of participants
Solifenacin 5 mg	Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 8 [N=387,397]	86.9 percentage of participants

Comparison: Week 4 Odds Ratio vs. Mirabegronp-value: 0.7495% CI: [0.76, 1.48]Regression, Logistic

Comparison: Week 8 Odds Ratio vs. Mirabegronp-value: 0.7495% CI: [0.71, 1.63]Regression, Logistic

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.2995% CI: [0.81, 2]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.2995% CI: [0.82, 1.9]Regression, Logistic

Secondary

Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit

A responder is defined as a participant with \>=10 points improvement in the total HRQL score from baseline.

Time frame: Baseline to Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit	Week 12 [N=865,859]	69.2 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit	Final visit [N=906,897]	67.5 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit	Week 12 [N=865,859]	72.6 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit	Final visit [N=906,897]	71.0 percentage of participants

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.03795% CI: [1.02, 1.62]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.04595% CI: [1.01, 1.57]Regression, Logistic

Secondary

Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit

A responder is defined as a participant with ≥1 point improvement in PPBC from baseline.

Time frame: Baseline to Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit	Week 12 [N=865,858]	73.1 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit	Final visit [N=906,897]	71.9 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit	Week 12 [N=865,858]	76.7 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit	Final visit [N=906,897]	74.9 percentage of participants

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.08295% CI: [0.97, 1.57]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.1595% CI: [0.94, 1.49]Regression, Logistic

Secondary

Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit

A responder is defined as a participant with ≥10 points improvement in symptom bother from baseline.

Time frame: Baseline to Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit	Week 12 [N=865,859]	77.5 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit	Final visit [N=906,897]	76.2 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit	Week 12 [N=865,859]	82.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit	Final visit [N=906,897]	81.2 percentage of participants

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.0195% CI: [1.08, 1.81]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.01195% CI: [1.07, 1.75]Regression, Logistic

Secondary

Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit

A responder is defined as a participant with \>=1 or \>=2 or \>=3 or \>=4 or \>=5 or 6-point improvement from baseline in TS-Likert scale.

Time frame: Baseline to final visit (up to Week 12)

Population: FAS population. LOCF was used.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥1 point improvement	85.6 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥2 point improvement	79.0 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥3 point improvement	66.7 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥4 point improvement	43.8 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥5 point improvement	15.4 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	6 point improvement	2.5 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥5 point improvement	15.1 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥1 point improvement	89.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥4 point improvement	46.6 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥2 point improvement	82.6 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	6 point improvement	2.8 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit	≥3 point improvement	70.8 percentage of participants

Comparison: Final visit (≥1 point improvement) Odds Rato vs. Mirabegronp-value: 0.01695% CI: [1.07, 1.93]Regression, Logistic

Comparison: Final visit (≥2 point improvement) Odds Rato vs. Mirabegronp-value: 0.06395% CI: [0.99, 1.62]Regression, Logistic

Comparison: Final visit (≥3 point improvement) Odds Rato vs. Mirabegronp-value: 0.05495% CI: [1, 1.53]Regression, Logistic

Comparison: Final visit (≥4 point improvement) Odds Rato vs. Mirabegronp-value: 0.1595% CI: [0.95, 1.46]Regression, Logistic

Comparison: Final visit (≥5 point improvement) Odds Rato vs. Mirabegronp-value: 0.7595% CI: [0.77, 1.44]Regression, Logistic

Comparison: Final visit (6 point improvement) Odds Rato vs. Mirabegronp-value: 0.6695% CI: [0.64, 2.04]Regression, Logistic

Secondary

Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12

A responder is defined as a participant with ≥1, ≥2, ≥3, ≥4, ≥5 or 6-point improvement from baseline in TS-Likert scale.

Time frame: Baseline to Week 12

Population: FAS population.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥4 point improvement	44.4 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥2 point improvement	80.3 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥3 point improvement	67.7 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥5 point improvement	15.6 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	6 point improvement	2.5 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥1 point improvement	86.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	6 point improvement	2.9 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥1 point improvement	90.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥5 point improvement	15.4 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥2 point improvement	83.6 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥3 point improvement	71.9 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12	≥4 point improvement	47.5 percentage of participants

Comparison: Week 12 (≥1 point improvement) Odds Rato vs. Mirabegronp-value: 0.00995% CI: [1.11, 2.06]Regression, Logistic

Comparison: Week 12 (≥2 point improvement) Odds Rato vs. Mirabegronp-value: 0.06595% CI: [0.99, 1.65]Regression, Logistic

Comparison: Week 12 (≥3 point improvement) Odds Rato vs. Mirabegronp-value: 0.05195% CI: [1, 1.55]Regression, Logistic

Comparison: Week 12 (≥4 point improvement) Odds Rato vs. Mirabegronp-value: 0.1495% CI: [0.95, 1.47]Regression, Logistic

Comparison: Week 12 (≥5 point improvement) Odds Rato vs. Mirabegronp-value: 0.8995% CI: [0.75, 1.4]Regression, Logistic

Comparison: Week 12 (6 point improvement) Odds Rato vs. Mirabegronp-value: 0.6695% CI: [0.64, 2.04]Regression, Logistic

Secondary

Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit

A responder is defined as a participant with ≥2 point improvement in PPBC from baseline.

Time frame: Baseline to Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit	Week 12 [N=865,858]	47.6 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit	Final visit [N=906,897]	46.2 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit	Week 12 [N=865,858]	52.6 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit	Final visit [N=906,897]	51.1 percentage of participants

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.05895% CI: [0.99, 1.53]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.06995% CI: [0.99, 1.5]Regression, Logistic

Secondary

Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit

A responder is defined as a participant who has ≥8 micturitions at baseline and has \<8 micturitions per 24 hours during the treatment period at each specified visit, where change from baseline is \<0.

Time frame: Week 4, Week 8, Week 12

Population: FAS population. LOCF was used for final visit only. N is the number of participants with available data at each timepoint.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 4 [N=916,906]	32.3 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 8 [N=888,876]	41.2 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 12 [N=870,856]	44.8 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Final visit [N=920,910]	44.2 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Final visit [N=920,910]	48.8 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 4 [N=916,906]	33.9 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 12 [N=870,856]	49.3 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit	Week 8 [N=888,876]	46.9 percentage of participants

Comparison: Week 4 Odds ratio vs. Mirabegronp-value: 0.6795% CI: [0.85, 1.28]Regression, Logistic

Comparison: Week 8 Odds ratio vs. Mirabegronp-value: 0.02695% CI: [1.03, 1.53]Regression, Logistic

Comparison: Week 12 Odds ratio vs. Mirabegronp-value: 0.1195% CI: [0.97, 1.44]Regression, Logistic

Comparison: Final Visit Odds ratio vs. Mirabegronp-value: 0.09395% CI: [0.97, 1.43]Regression, Logistic

Secondary

Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit

A responder is defined as a participant who reported incontinence episodes at baseline and reported no incontinence episodes during the treatment period at specified visit.

Time frame: Week 4, Week 8, Week 12

Population: FAS-I population. LOCF was used for final visit only. N is the number of participants with available data at each time point.

Arm	Measure	Group	Value (NUMBER)
Mirabegron 50 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4 [N=404,410]	47.3 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 8 [N=387,397]	64.3 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 12 [N=381,387]	69.0 percentage of participants
Mirabegron 50 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Final visit [N=404,413]	67.3 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Final visit [N=404,413]	68.5 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 4 [N=404,410]	52.0 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 12 [N=381,387]	69.5 percentage of participants
Solifenacin 5 mg	Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit	Week 8 [N=387,397]	63.2 percentage of participants

Comparison: Week 4 Odds Ratio vs. Mirabegronp-value: 0.295% CI: [0.9, 1.67]Regression, Logistic

Comparison: Week 8 Odds Ratio vs. Mirabegronp-value: 0.5795% CI: [0.65, 1.26]Regression, Logistic

Comparison: Week 12 Odds Ratio vs. Mirabegronp-value: 0.9295% CI: [0.69, 1.39]Regression, Logistic

Comparison: Final visit Odds Ratio vs. Mirabegronp-value: 0.995% CI: [0.73, 1.42]Regression, Logistic

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours

Change From Baseline in Mean Number of Nocturia Episodes Per 24 Hours After 4, 8 and 12 Weeks of Treatment

Change From Baseline in Mean Number of Pads Used Per 24 Hours After 4, 8 and 12 Weeks of Treatment

Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Level of Urgency

Change From Baseline to 4, 8 and 12 Weeks of Treatment and at the Final Visit in Mean Number of Urgency Episodes (Grade 3 or 4) Per 24 Hours

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Incontinence Episodes Per 24 Hours

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Micturitions Per 24 Hours

Change From Baseline to 4, 8 and 12 Weeks of Treatment in Mean Number of Urgency Incontinence Episodes Per 24 Hours

Change From Baseline to Final Visit in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Final Visit in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Final Visit in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Final Visit in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Final Visit in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction Questionnaire-Likert Scale

Change From Baseline to Week 12 and the Final Visit in the Patient's Assessment of Treatment Satisfaction (TS)-Visual Analog Scale (VAS)

Change From Baseline to Week 12 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 12 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 12 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 12 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 12 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 4 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 4 in Mobility Scores as Assessed by the European Quality of Life 5-Dimensions (EQ-5D-5L) Questionnaire

Change From Baseline to Week 4 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 4 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 4 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 8 in Anxiety/Depression Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 8 in Mobility Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 8 in Pain/Discomfort Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 8 in Self-care Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Week 8 in Usual Activities Scores as Assessed by the EQ-5D-5L Questionnaire

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Patient Perception of Bladder Condition (PPBC)

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Symptom Bother Score as Assessed by the Overactive Bladder Questionnaire (OAB-q)

Change From Baseline to Weeks 4, 8, 12, and at the Final Visit in Total Health-Related Quality of Life (HRQoL) Score as Assessed by the OAB-q

Number of Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

Number of Nocturia Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

Number of Pads Used at 4, 8 and 12 Weeks of Treatment and at the Final Visit

Number of Urgency Incontinence Episodes at 4, 8 and 12 Weeks of Treatment and at the Final Visit

Percentage of Participants Reporting at Least One Treatment-emergent Adverse Event of Dry Mouth, Constipation or Blurred Vision During Double-blind Treatment Period

Percentage of Participants With 50% Reduction in Incontinence Episodes at Weeks 4, 8, 12 and Final Visit

Percentage of Participants With Improvement in HRQoL Scales as Assessed by the OAB-q: ≥10 Points Improvement in OAB-q at Week 12 and Final Visit

Percentage of Participants With Improvement in PPBC: ≥1 Point Improvement at Week 12 and Final Visit

Percentage of Participants With Improvement in Symptom Bother Score as Assessed by the OAB-q: ≥ 10 Points Improvement in OAB-q at Week 12 and Final Visit

Percentage of Participants With Improvement in Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Final Visit

Percentage of Participants With Improvement of Treatment Satisfaction Questionnaire - Likert Scale: ≥1, ≥2, ≥3, ≥4, ≥5, and 6-point Improvement From Baseline to Week 12

Percentage of Participants With Major Improvement in PPBC: ≥2 Point Improvement at Week 12 and Final Visit

Percentage of Participants With Normalization of Micturitions at Weeks 4, 8, 12 and Final Visit

Percentage of Participants With Zero Incontinence Episodes at Weeks 4, 8, 12 and Final Visit